BioLineRx: Positive Results for Potential Standard of Care in Stem Cell Study

 - Results demonstrate significant cost benefits of using Motixafortide in combination with G-CSF as standard-of-care mobilization therapy for all multiple myeloma patients undergoing autologous stem cell transplantation -

- Results from pre-planned study, on top of highly significant and clinically meaningful results from Phase 3 GENESIS trial announced in May 2021, strongly support potential use of Motixafortide as standard of care in stem cell mobilization -

https://finance.yahoo.com/news/biolinerx-announces-positive-results-pharmacoeconomic-123000351.html